Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials

被引：63
作者：
Salas M. [1 ]
Ward A. [1 ]
Caro J. [1 ,2 ]
机构：
[1] Caro Research Institute, Concord, MA 01742
[2] Div. of General Internal Medicine, McGill University, Montreal, Que.
来源：
BMC Gastroenterology | / 2卷 / 1期
关键词：
Omeprazole; Duodenal Ulcer; Proton Pump Inhibitor; Ranitidine; Gastric Ulcer;
D O I：
10.1186/1471-230X-2-17
中图分类号：
学科分类号：
摘要：
Background: Gastric ulcers are a frequent problem in the United States. Proton pump inhibitors have been shown to increase healing rates and improve clinical symptoms. The objective of this study is to compare gastric ulcer healing rates for patients treated with a proton pump inhibitor (PPI) (omeprazole, rabeprazole, pantoprazole, or lansoprazole), an histamine 2- receptor antagonist (ranitidine) or placebo. Methods: A literature search was conducted to identify randomized, controlled clinical trials that included a PPI in at least one treatment arm and assessed the gastric ulcer healing rates endoscopically. The healing rates were estimated for each treatment at specific time points, and Rate Ratios (RR) and 95% confidence intervals (CI) were estimated for each trial. Results: Sixteen trials met the inclusion criteria: four compared a PPI versus placebo, nine compared a PPI versus ranitidine (no trials of rabeprazole versus ranitidine met the inclusion criteria), and three compared a newer PPI (lansoprazole, pantoprazole or rabeprazole) versus omeprazole. In relation to ranitidine, the pooled RR of PPIs (lansoprazole, omeprazole and pantoprazole) was 1.33 (95% CI 1.24 to 1.42) at four weeks. In each trial, greater improvement in the studied clinical symptoms was found with the newer PPIs (rabeprazole, pantoprazole and lansoprazole) when compared to omeprazole. Conclusion: In this study treatment with PPIs resulted in higher healing rates than ranitidine or placebo. This evidence suggests that the first choice for gastric ulcer treatment for the greater relief of symptoms is one of the newer PPIs. © 2002 Salas et al; licensee BioMed Central Ltd.
引用
收藏
页数：7
相关论文
共 33 条
[1]  
Kurata J.H., Haile B.M., Epidemiology of peptic ulcer disease, Clin. Gastroenterol., 13, pp. 289-307, (1984)
[2]  
Florent C., Progress with proton pump inhibitors in acid peptic disease: Treatment of duodenal and gastric ulcer, Clin. Ther., 15, SUPPL. B, pp. 14-21, (1993)
[3]  
Hasebe T., Harasawa S., Miwa T., Factors affecting depth of gastric ulcers, Tokai J. Exp. Clin. Med., 23, pp. 177-182, (1998)
[4]  
Sontag S.J., Guilty as charged: Bugs and drugs in gastric ulcer, Am. J. Gastroenterol., 92, pp. 1255-1261, (1997)
[5]  
Hasebe T., Harasawa S., Miwa T., Factors affecting depth of gastric ulcers, Tokai J. Exp. Clin. Med., 23, pp. 177-182, (1998)
[6]  
Sachs G., Chang H.H., Rabon E., Schackman R., Lewin M., Saccomani G., A non electrogenic H+ pump in plasma membranes of hog stomach, J. Biol. Chem., 251, pp. 7960-7968, (1976)
[7]  
Sachs G., Shin J.M., Besancon M., Prinz C., The continuing development of gastric acid pump inhibitors, Aliment Pharmacol. Ther., 7, SUPPL. 1, pp. 4-12, (1993)
[8]  
Schepp W., Proton pump inhibitory therapy: Then and now, Yale J. Biol. Med., 69, pp. 175-186, (1996)
[9]  
Earnest D.L., Treatment advances in acid secretory disorders: The promise of rapid symptom relief with disease resolution, Am. J. Gastroenterol., 94, SUPPL., (1999)
[10]  
Robinson M., New-generation proton-pump inhibitors: Overcoming the limitations of early-generation agents, Eur. J. Gastroenterol. Hepatol., 13, SUPPL. 1, (2001)
1234